

FATE THERAPEUTICS INC
Form SC 13G/A
February 14, 2018

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G/A

**Under the Securities Exchange Act of 1934
(Amendment No. 1)***

FATE THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

31189P102

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | |
|-----|--|
| 1. | Name of Reporting Persons
Venrock Associates V, L.P. |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) <input checked="" type="checkbox"/> (1)
(b) <input type="checkbox"/> (0) |
| 3. | SEC Use Only |
| 4. | Citizenship or Place of Organization
Delaware |
| 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
2,473,187(2) |
| 7. | Sole Dispositive Power
0 |
| 8. | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) |
| 12. | Type of Reporting Person (See Instructions)
PN |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer s common stock outstanding as of October 31, 2017 as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | | |
|-----|---|--|
| 1. | Name of Reporting Persons
Venrock Partners V, L.P. | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| | (a) <input checked="" type="checkbox"/> | (1) |
| | (b) <input type="checkbox"/> | o |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization
Delaware | |
| 5. | | Sole Voting Power
0 |
| 6. | | Shared Voting Power
2,473,187(2) |
| 7. | | Sole Dispositive Power
0 |
| 8. | | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) | |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) | |
| 12. | Type of Reporting Person (See Instructions)
PN | |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer s common stock outstanding as of October 31, 2017 as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | | |
|-----|---|--|
| 1. | Name of Reporting Persons
Venrock Entrepreneurs Fund V, L.P. | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| | (a) <input checked="" type="checkbox"/> | (1) |
| | (b) <input type="checkbox"/> | o |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization
Delaware | |
| 5. | | Sole Voting Power
0 |
| 6. | | Shared Voting Power
2,473,187(2) |
| 7. | | Sole Dispositive Power
0 |
| 8. | | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) | |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) | |
| 12. | Type of Reporting Person (See Instructions)
PN | |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer s common stock outstanding as of October 31, 2017 as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | |
|-----|--|
| 1. | Name of Reporting Persons
Venrock Management V, LLC |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)
(a) <input checked="" type="checkbox"/> (1)
(b) <input type="checkbox"/> (0) |
| 3. | SEC Use Only |
| 4. | Citizenship or Place of Organization
Delaware |
| 5. | Sole Voting Power
0 |
| 6. | Shared Voting Power
2,473,187(2) |
| 7. | Sole Dispositive Power
0 |
| 8. | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="checkbox"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) |
| 12. | Type of Reporting Person (See Instructions)
OO |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer's common stock outstanding as of October 31, 2017 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | | |
|-----|---|--|
| 1. | Name of Reporting Persons
Venrock Partners Management V, LLC | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| | (a) <input checked="" type="checkbox"/> (1) | |
| | (b) <input type="checkbox"/> (0) | |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization
Delaware | |
| 5. | | Sole Voting Power
0 |
| 6. | | Shared Voting Power
2,473,187(2) |
| 7. | | Sole Dispositive Power
0 |
| 8. | | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) | |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> (0) |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) | |
| 12. | Type of Reporting Person (See Instructions)
OO | |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer's common stock outstanding as of October 31, 2017 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 31189P102

- | | | |
|-----|---|--|
| 1. | Name of Reporting Persons
VEF Management V, LLC | |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) | |
| | (a) <input checked="" type="checkbox"/> | (1) |
| | (b) <input type="checkbox"/> | o |
| 3. | SEC Use Only | |
| 4. | Citizenship or Place of Organization
Delaware | |
| 5. | | Sole Voting Power
0 |
| 6. | | Shared Voting Power
2,473,187(2) |
| 7. | | Sole Dispositive Power
0 |
| 8. | | Shared Dispositive Power
2,473,187(2) |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
2,473,187(2) | |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) | <input type="checkbox"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.7%(3) | |
| 12. | Type of Reporting Person (See Instructions)
OO | |

(1) Venrock Associates V, L.P., Venrock Partners V, L.P. and Venrock Entrepreneurs Fund V, L.P. (collectively, the Venrock Entities) and the general partner of each Venrock Entity respectively, Venrock Management V, LLC, Venrock Partners Management V, LLC and VEF Management V, LLC (collectively, the Venrock GPs) are members of a group for purposes of this Schedule 13G/A. The Venrock Entities and the Venrock GPs are collectively referred to herein as the Reporting Persons.

(2) Consists of 2,231,558 shares of common stock owned by Venrock Associates V, L.P., 189,198 shares of common stock owned by Venrock Partners V, L.P. and 52,431 shares of common stock owned by Venrock Entrepreneurs Fund V, L.P.

(3) This percentage is calculated based (a) 41,685,695 shares of the Issuer s common stock outstanding as of October 31, 2017 as reported in the Issuer s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 1, 2017 and (b) 10,953,750 shares of common stock issued pursuant to an underwritten public offering that closed on December 15, 2017.

Edgar Filing: FATE THERAPEUTICS INC - Form SC 13G/A

Introductory Note: This Statement on Schedule 13G/A is filed on behalf of Venrock Associates V, L.P., a limited partnership organized under the laws of the State of Delaware, Venrock Partners V, L.P., a limited partnership organized under the laws of the State of Delaware, Venrock Entrepreneurs Fund V, L.P., a limited partnership organized under the laws of the State of Delaware (collectively, the Venrock Entities), as well as Venrock Management V, LLC, a limited liability company organized under the laws of the State of Delaware, Venrock Partners Management V, LLC, a limited liability company organized under the laws of the State of Delaware and VEF Management V, LLC, a limited liability company organized under the laws of the State of Delaware (collectively, the Venrock GPs) in respect of shares of common stock of Fate Therapeutics, Inc.

Item 1.

- (a) Name of Issuer
Fate Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices
3535 General Atomics Court, Suite 200
San Diego, California 92121

Item 2.

- (a) Name of Person Filing
Venrock Associates V, L.P.
Venrock Partners V, L.P.
Venrock Entrepreneurs Fund V, L.P.
Venrock Management V, LLC
Venrock Partners Management V, LLC
VEF Management V, LLC
- (b) Address of Principal Business Office or, if none, Residence

New York Office:

Palo Alto Office:

Boston Office:

530 Fifth Avenue
22nd Floor
New York, NY 10036

3340 Hillview Avenue
Palo Alto, CA 94304

34 Farnsworth Street
3rd Floor
Boston, MA 02210

- (c) Citizenship
Each of the Venrock Entities are limited partnerships organized in the State of Delaware. Each of the Venrock GPs are limited liability companies organized in the State of Delaware.
- (d) Title of Class of Securities
Common Stock
- (e) CUSIP Number
31189P102

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable